| Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology | 2019/05/01 | | 812 |
| NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors | 2010/04/01 | English | 786 |
| Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology | 2017/04/01 | English | 761 |
| Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology | 2021/03/01 | | 694 |
| Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology | 2017/08/01 | English | 648 |
| Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology | 2016/10/01 | English | 628 |
| Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology | 2018/07/01 | English | 617 |
| Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology | 2019/01/01 | English | 588 |
| Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology | 2020/07/01 | | 569 |
| Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology | 2019/07/01 | | 568 |
| NCCN Guidelines Insights: Colon Cancer, Version 2.2018 | 2018/04/01 | English | 567 |
| NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021 | 2021/03/01 | | 545 |
| Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology | 2022/02/01 | | 538 |
| Cancer-Related Fatigue, Version 2.2015 | 2015/08/01 | English | 517 |
| Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology | 2020/04/01 | | 503 |
| Prostate Cancer | 2010/02/01 | | 499 |
| Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology | 2022/05/01 | | 497 |
| Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology | 2017/03/01 | English | 490 |
| Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology | 2021/04/01 | | 490 |
| Prostate Cancer, Version 1.2016 | 2016/01/01 | English | 464 |
| NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020 | 2019/12/01 | | 449 |
| Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology | 2018/02/01 | English | 425 |
| Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology | 2021/05/01 | | 424 |
| Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology | 2021/01/06 | | 415 |
| Non–Small Cell Lung Cancer | 2010/07/01 | | 413 |
| Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology | 2018/05/01 | English | 394 |
| NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018 | 2018/05/01 | English | 378 |
| Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology | 2017/06/01 | English | 365 |
| Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology | 2020/03/01 | | 353 |
| Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology | 2019/03/11 | | 349 |